CASI Pharmaceuticals (CASIF) EBITDA Margin (2022 - 2025)
CASI Pharmaceuticals' (CASIF) quarterly EBITDA Margin came in at 1068.86% in Q4 2025, down 97217.0% YoY from N/an in Q4 2024, and down 207.83% on a QoQ basis from 347.22% in Q3 2025.
CASI Pharmaceuticals (CASIF) EBITDA Margin (2022 - 2025) Analysis & Trends
CASI Pharmaceuticals (CASIF) has 4 years of EBITDA Margin data on file, last reported at 1068.86% in Q4 2025.
- Quarterly EBITDA Margin fell 97217.0% year-over-year to 1068.86% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 528.07% (down 38923.0% YoY) and the FY2025 annual result came in at 217.3%, down 7846.0% from the prior year.
- EBITDA Margin slipped to 1068.86% in Q4 2025, from 347.22% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 49.85% in Q4 2023 to a low of 1068.86% in Q4 2025.
- A 4-year average of 199.7% and a median of 102.65% in 2024 frame the typical range for EBITDA Margin.
- The widest YoY moves for EBITDA Margin: up 11099 bps in 2025, down 97217 bps in 2025.
- Tracing CASIF's EBITDA Margin over 4 years: stood at 145.89% in 2022, then surged by 66 bps to 49.85% in 2023, then plunged by 94 bps to 96.69% in 2024, then sank by 1005 bps to 1068.86% in 2025.
- The last three EBITDA Margin figures came in at 1068.86% (Q4 2025), 347.22% (Q3 2025), and 266.47% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.23 Bn | 132.38 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.97 Bn | 78.97 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 59.88 Bn | 54.74 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.20 Bn | 37.11 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.69 Bn | 10.30 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.16 Bn | 26.33 Bn | - | 19.75% |
| 10 | CASI Pharmaceuticals | 2.65 Mn | -3.76 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1,068.86% |
| Sep 30, 2025 | -347.22% |
| Jun 30, 2025 | -266.47% |
| Mar 31, 2025 | -166.33% |
| Dec 31, 2024 | -96.69% |
| Sep 30, 2024 | -108.61% |
| Jun 30, 2024 | -220.88% |
| Mar 31, 2024 | -277.32% |
| Dec 31, 2023 | -49.85% |
| Sep 30, 2023 | -57.65% |
| Jun 30, 2023 | -95.16% |
| Mar 31, 2023 | -86.41% |
| Dec 31, 2022 | -145.89% |
| Sep 30, 2022 | -55.98% |
| Jun 30, 2022 | -74.75% |
| Mar 31, 2022 | -77.09% |